Sara Guirao S谩nchez路 @guirao_sara 路 X路路 1 day agoScore70
Body 路 original
馃珌 #ESMO26 Krascendo 1 (ph III): divarasib beats soto/ada head-to-head in 2L+ KRAS G12C NSCLC
PFS 9.8 vs 5.7 mo (HR 0.58)
OS 17.7 vs 12.0 mo (HR 0.56)
ORR 58% vs 32%
Likely new 2L SoC. Caveats: control 91% sotorasib, immature OS, GI tox (diarrhea ~60% in ph I).
51 views 路 2 likes 路 2 reposts 路 0 replies
Conference abstracts
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgSource: Sara Guirao S谩nchez 路 x.com